title: Management options for established chemotherapy-induced peripheral neuropathy.
abstract: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a variety of chemotherapeutic agents. Clinicians are cognizant of the negative impact of CIPN on cancer treatment outcomes and patients' psychosocial functioning and quality of life. In an attempt to alleviate this problem, clinicians and patients try various therapeutic interventions, despite limited evidence to support efficacy of these treatments. The rationale for such use is mostly based on the evidence for the treatment options in non-CIPN peripheral neuropathy syndromes, as this area is more robustly studied than is CIPN treatment. In this manuscript, we examine the existing evidence for both CIPN and non-CIPN treatments and develop a summary of the best available evidence with the aim of developing a practical approach to the treatment of CIPN, based on available literature and clinical practice experience.
authors.affiliation: Division of Medical Oncology, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA, pachman.deirdre@mayo.edu.
authors.forename: Deirdre R
authors.initials: DR
authors.lastname: Pachman
authors.forename: James C
authors.initials: JC
authors.lastname: Watson
authors.forename: Maryam B
authors.initials: MB
authors.lastname: Lustberg
authors.forename: Nina D
authors.initials: ND
authors.lastname: Wagner-Johnston
authors.forename: Alexandre
authors.initials: A
authors.lastname: Chan
authors.forename: Larry
authors.initials: L
authors.lastname: Broadfield
authors.forename: Yin Ting
authors.initials: YT
authors.lastname: Cheung
authors.forename: Christopher
authors.initials: C
authors.lastname: Steer
authors.forename: Dawn J
authors.initials: DJ
authors.lastname: Storey
authors.forename: Kavita D
authors.initials: KD
authors.lastname: Chandwani
authors.forename: Judith
authors.initials: J
authors.lastname: Paice
authors.forename: Pascal
authors.initials: P
authors.lastname: Jean-Pierre
authors.forename: Jeong
authors.initials: J
authors.lastname: Oh
authors.forename: Jayesh
authors.initials: J
authors.lastname: Kamath
authors.forename: Marie
authors.initials: M
authors.lastname: Fallon
authors.forename: Herwig
authors.initials: H
authors.lastname: Strik
authors.forename: Susanne
authors.initials: S
authors.lastname: Koeppen
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents